# Long-term follow-up after childhood, teenage and young adult cancer, planned by the treatment received

Source: https://onco.cc/protocols/long-term-follow-up-after-childhood-cancer/  
OnCo record `long-term-follow-up-after-childhood-cancer` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

After cancer treatment in childhood or young adulthood, follow-up is planned around the treatment a person had. Each survivor should have a written summary of every medicine with its total dose, every radiotherapy area and every operation, and from it a personal plan of checks, such as heart scans, breast screening or hearing tests. The plan should carry on for life, under a survivorship service.

## Summary

The COG Long-Term Follow-Up Guidelines (Version 6.0, October 2023; 165 exposure sections and 45 patient Health Links) are the most complete exposure-based guideline. They apply from two or more years after the end of treatment to survivors with no symptoms, and work in three moves: obtain the cancer treatment summary (agents, cumulative anthracycline dose in doxorubicin equivalents, radiation fields, with the total dose for the fields where COG still uses one, surgery, transplant and chronic graft-versus-host disease status); compile the sections that apply; and build an individual screening plan. By COG's own count 68 per cent of sections rest mainly on history and examination, 27 per cent include periodic tests and 5 per cent recommend no screening. COG scores each section by expert consensus (1, 2A, 2B) and states that no randomised trial of screening exists in this population. The IGHG harmonises individual topics and grades both the evidence and the strength of each recommendation: cardiomyopathy (2022), breast cancer (2020 and 2025), thyroid cancer (2018), ototoxicity (2019), premature ovarian insufficiency (2016) and male gonadotoxicity (2017) are summarised in the steps. In Europe the PanCareFollowUp recommendations (2021) combine the IGHG guidelines with 25 pragmatic recommendations for topics IGHG has not yet covered, and PanCareSurFup (2019) recommends that risk-adapted follow-up under a survivorship expert service be available to every survivor throughout life, starting no later than 5 years after treatment or 5 years from diagnosis, depending on the health system. Tools that turn a treatment record into a personal plan are Passport for Care (COG) and the European Survivorship Passport.

Where the sources differ: COG examines the thyroid by hand every year after radiation to the head or brain, neck or spine (cervical or whole) or total body irradiation, while IGHG makes thyroid cancer surveillance a shared decision between palpation every 1 to 2 years, ultrasound every 3 to 5 years, or no surveillance; for breast screening IGHG recommends surveillance from 10 Gy or more to the chest, while COG Version 6.0 lists radiation to the chest or axilla or total body irradiation without a minimum dose; COG counts radiation to the chest, abdomen, spine (thoracic or whole) and total body irradiation as radiation with potential impact to the heart, where IGHG speaks of chest-directed radiotherapy; SIGN 132 (2013) and the UK aftercare pathways sort survivors into three levels of follow-up intensity, which COG and IGHG do not. This page explains how follow-up is organised; a survivor's own long-term follow-up team decides the plan, and their plan comes first.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: late effects clinic; long-term follow-up clinic; LTFU; exposure-based follow-up; risk-based survivorship care; COG Long-Term Follow-Up Guidelines; survivorship passport; SurPass; Passport for Care; aftercare after childhood cancer; transition to adult care after childhood cancer

## Connected records

- protocols: [Breast screening after chest radiotherapy at a young age](https://onco.cc/protocols/breast-screening-after-chest-radiotherapy-at-a-young-age/), [End of treatment: treatment summary, survivorship care plan and handover to primary care](https://onco.cc/protocols/survivorship-care-plan-and-treatment-summary/), [Fertility preservation for children and young people before cancer treatment](https://onco.cc/protocols/paediatric-fertility-preservation/), [Hearing protection for children receiving cisplatin](https://onco.cc/protocols/paediatric-cisplatin-hearing-protection/), [Heart scans after anthracyclines or chest radiotherapy for cancer in childhood, adolescence or young adulthood](https://onco.cc/protocols/cardiomyopathy-surveillance-after-childhood-cancer/), [Second cancers caused by cancer drugs: monitoring on PARP inhibitors, BRAF inhibitors, lenalidomide, tamoxifen, radioligands and CAR T cells](https://onco.cc/protocols/second-cancers-after-anticancer-drug-treatment/)
- collections: [International Guideline Harmonization Group for late effects of childhood cancer](https://onco.cc/collections/ighg/), [PanCareSurFup and the European survivor cohorts](https://onco.cc/collections/pancaresurfup/)
- technologies: [How much illness childhood cancer survivors carry, and at what age](https://onco.cc/technologies/rejuv-paed-chronic-disease-burden/), [Long-term follow-up in the United Kingdom: what a survivor is actually offered](https://onco.cc/technologies/rejuv-paed-uk-long-term-follow-up/), [Second cancers after childhood cancer: the risk by treatment, and why it is falling](https://onco.cc/technologies/rejuv-paed-second-cancers/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/), [The Children's Oncology Group Long-Term Follow-Up Guidelines](https://onco.cc/technologies/rejuv-paed-cog-ltfu-guidelines/), [The handover from children's to adult services, where follow-up falls away](https://onco.cc/technologies/rejuv-paed-transition-to-adult-care/), [The heart after anthracyclines and chest radiotherapy in childhood](https://onco.cc/technologies/rejuv-paed-heart/)
- ideas: [Survivorship care plans generated automatically from the treatment record](https://onco.cc/ideas/idea-acc-auto-generated-survivorship-plans/)
- cancers: [Adolescent and young adult cancers (ages 15 to 39)](https://onco.cc/cancers/aya-cancers/), [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/)
- fronts: [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- companies: [Children's Oncology Group (COG)](https://onco.cc/companies/childrens-oncology-group/)
- terms: [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/)
- bottlenecks: [Fragmented care and guideline gaps](https://onco.cc/bottlenecks/b-care-fragmentation/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/)

---
JSON: https://onco.cc/api/v1/entities/long-term-follow-up-after-childhood-cancer.json